May 19, 2022
  • May 19, 2022
  • Home
  • Wire Transfer
  • TopNewsGuide: STAB ‘Well Positioned’ for 2022 Growth, Phase 3 Update

TopNewsGuide: STAB ‘Well Positioned’ for 2022 Growth, Phase 3 Update

By on February 28, 2022 0

Statera Biopharma, Inc. (NASDAQ:STAB) announced a preliminary unaudited volume of $1,487,036 for 2021. Michael K. HandleyCEO of STAB, says the company’s “clinical-stage pipeline” is well-positioned to reach “numerous milestones” in 2022.

This clinical-stage biopharmaceutical company is investigating the treatment of pediatric Crohn’s disease. He is also studying the treatment of patients with acute COVID-19 infection.

Investors should put STAB stocks on their watchlists as clinical-stage biopharmaceutical companies rise in valuation

STAB PRODUCES REGISTERED INVESTMENTS FOR FUND STUDIES

Handley adds, “Following the recent FDA submission of our Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn’s disease, we plan to use proceeds from our registered direct offering to launch patient recruitment in the second quarter.

These dollars will also be used to add the recruitment of patients with acute COVID-19 infection into its STAT-205 study. The STAB hopes to develop preliminary data from this study this year.

STAB RELEASES ITS 2021 FINANCIAL RESULTS

One of the company’s catalysts is the construction of its infrastructure. Here are the highlights of its new financial statements:

– Volume increased by 100% to $1,487,036 following the acquisition of ImQuest Life Sciences, Inc.and its subsidiaries (ImQuest) in June 2021 by Old Cytocom.

– Due to the acquisition, the cost of revenue related to the transaction was $488,314. Revenue cost was approximately 33% as a percentage of revenue for 2021.

– R&D expenditure increased in 2021 to $31,587,000i.e. 191% more than its $10,501,668 in 2020.

– The increase in R&D is the result of increased costs for expanded clinical trial programs in Crohn’s disease and COVID-19 in 2021.

– Other expenses also increased for 2021 to $4,328,823, an increase of 172% year-on-year. This is mainly due to an increase in $5,458,954 interest and offset by an increase of $2,772,324 in gains on extinguishment of debt.

– Net loss for 2021 was $34,892,762a jump of 189% compared to the comparable period in 2020.

HANDLEY, CEO STAB, OPTIMISTIC ON 2022 PERFORMANCE

“We have taken many steps to continue the development of our clinical-stage pipeline, which positions us well to achieve many milestones in 2022,” said Michael K. HandleyCEO.

The STAB develops new immunotherapies targeting emerging autoimmune viruses, neutropenia/anemia and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.

STAB ADDS TO ITS COUNCIL

STAB has also added to its board of directors Satish ChandranHe is Ph.D., President and Chief Executive Officer of Lays Sciences, Inc. and CEO of PhysisPharma, Inc. Steve Barbarick resigned as Director and will transition to an advisory role.

“We are delighted to welcome Dr Chandrana biotechnology veteran with more than 30 years of experience in the development and commercialization of drugs, biologics and medical devices, to our Board of Directors at this exciting time as Statera Biopharma advances our pipeline toward multiple clinical milestones,” said Handley, President and CEO.

Dr Chandranadds: “Statera Biopharma is on track to achieve multiple clinical milestones in 2022, which will benefit patients with conditions ranging from Crohn’s disease to SARS-CoV-2 viral infections. »

Keep STAB stock on your Watchlist as biopharmaceutical companies increase in value as clinical research studies intensify. Link to more news at https://www.staterabiopharma.com/

Disclaimer: TopNewsGuide ‘TNG’ is responsible for the production and distribution of this content. TNG is not operated by a licensed dealer, dealer or registered investment adviser. It should be expressly understood that in no way does the information published here represent a recommendation to buy or sell a security. Our reports/press releases are commercial advertising and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in stocks featured on our site or in emails unless you can afford to lose your entire investment. The information made available by TNG is not intended to be, nor does it constitute, investment advice or recommendations. Contributors can buy and sell titles before and after any particular article, report, and publication. By no means TNG. be liable to any member, guest or third party for any damages of any kind arising from the use of any content or other material published or made available by TNG, including, without limitation, any loss of investment, loss of profit, opportunity special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. TNG. strongly urges you to conduct a full and independent investigation of the respective companies and consider all relevant risks. Readers are invited to consult SECOND periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For certain content, TNG., its authors, contributors or agents may be compensated for the preparation of research, video graphics and editorial content. TNG was compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. In connection with this content, readers, subscribers and website visitors should read the full disclaimers and financial statement found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor regarding forward-looking statements. Any statements that express or imply discussions regarding predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made, which involve a number of risks and uncertainties that could cause actual results or events to differ materially from those currently anticipated. . Forward-looking statements in this action can be identified by the use of words such as plans, foresee, expect, anticipate, estimate, believe, understand, or by statements indicating certain actions and quote; can, could or could happen. Understand that there is no guarantee that past performance will be indicative of future results. Investing in microcap and growth stocks is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or depreciated due to the speculative nature of the companies featured.

CONTACT: Marc McKelvie

[email protected]

(754) 233-0966

.